WO2009091230A3 - 유방암 모니터링,진단 및 스크리닝용 단백질 마커 및 이를 이용한 유방암 모니터링,진단 및 스크리닝 방법 - Google Patents

유방암 모니터링,진단 및 스크리닝용 단백질 마커 및 이를 이용한 유방암 모니터링,진단 및 스크리닝 방법 Download PDF

Info

Publication number
WO2009091230A3
WO2009091230A3 PCT/KR2009/000279 KR2009000279W WO2009091230A3 WO 2009091230 A3 WO2009091230 A3 WO 2009091230A3 KR 2009000279 W KR2009000279 W KR 2009000279W WO 2009091230 A3 WO2009091230 A3 WO 2009091230A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast
cancer
diagnosis
screening
monitoring
Prior art date
Application number
PCT/KR2009/000279
Other languages
English (en)
French (fr)
Other versions
WO2009091230A2 (ko
Inventor
김철우
박필제
이경애
강경남
신용성
노동영
김병권
Original Assignee
주식회사 바이오인프라
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 바이오인프라 filed Critical 주식회사 바이오인프라
Publication of WO2009091230A2 publication Critical patent/WO2009091230A2/ko
Publication of WO2009091230A3 publication Critical patent/WO2009091230A3/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

본 발명은 유방암 모니터링, 진단 및 스크리닝용 단백질 마커, 및 이를 이용한 유방암 모니터링, 진단 및 스크리닝 방법에 관한 것으로, 보다 상세하게는 유방암 환자에게서 특이적으로 발현이 증가 또는 감소하는 단백질 마커를 이용하여 유방암을 모니터링, 진단 및 스크리닝하는 방법에 관한 것이다. 본 발명의 단백질 마커를 이용한 유방암 모니터링, 진단 및 스크리닝 방법은 정상인과 유방암 환자에서 마커 단백질 발현량의 차이를 확인하여 유방암의 조기 진단 및 스크리닝, 및 유방암 진행 정도 평가를 가능하게 함으로써 신속한 치료가 가능하게 하여 유방암 환자의 생존율을 향상시키고 암 치료로 인한 국가적 손실을 줄이는데 기여할 수 있다.
PCT/KR2009/000279 2008-01-18 2009-01-19 유방암 모니터링,진단 및 스크리닝용 단백질 마커 및 이를 이용한 유방암 모니터링,진단 및 스크리닝 방법 WO2009091230A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20080005693 2008-01-18
KR10-2008-0005693 2008-01-18

Publications (2)

Publication Number Publication Date
WO2009091230A2 WO2009091230A2 (ko) 2009-07-23
WO2009091230A3 true WO2009091230A3 (ko) 2009-10-08

Family

ID=40885824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/000279 WO2009091230A2 (ko) 2008-01-18 2009-01-19 유방암 모니터링,진단 및 스크리닝용 단백질 마커 및 이를 이용한 유방암 모니터링,진단 및 스크리닝 방법

Country Status (2)

Country Link
KR (1) KR101122647B1 (ko)
WO (1) WO2009091230A2 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101144323B1 (ko) * 2009-12-30 2012-05-11 한국과학기술연구원 유방암 진단용 자가항체마커 및 이의 조합으로 구성된 다중마커진단 키트
KR101142443B1 (ko) * 2010-05-18 2012-05-11 한국생명공학연구원 폐암 진단용 Ｃｏｌ１０Ａ１ 마커 및 이를 이용한 진단 키트
AU2012327215A1 (en) * 2011-02-16 2013-09-26 The Gov't of the USA, as represented by The Sec'y, Dept of Hlth and Hum'n Srvcs, Ctrs for Disease Ctrl & Prvn Detection of subject biomarker diagnostic assay for dengue fever and the differentiation of dengue hemorrhagic fever
KR101431062B1 (ko) * 2012-03-08 2014-08-21 (주)바이오메디앙 유방암 진단용 다중 바이오마커 세트, 이의 검출 방법 및 이에 대한 항체를 포함하는 유방암 진단키트
CN110716043B (zh) * 2019-10-23 2023-02-28 郑州大学 一种用于乳腺癌早期筛查和诊断的血清蛋白标志物、试剂盒及检测方法
CN111190008B (zh) * 2020-01-07 2022-03-11 中山大学孙逸仙纪念医院 血清mpo-dna在预测乳腺癌预后抑制乳腺癌远处器官转移中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050100371A (ko) * 2003-01-13 2005-10-18 에모리 유니버시티 정상 및 암세포에서의 유전자 발현의 검출 방법
KR100679173B1 (ko) * 2006-02-28 2007-02-06 주식회사 바이오인프라 위암 진단용 단백질 마커 및 이를 이용한 진단키트
US20070117123A1 (en) * 2005-09-14 2007-05-24 The Regents Of The University Of California Salivary protein and rna for breast cancer detection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050100371A (ko) * 2003-01-13 2005-10-18 에모리 유니버시티 정상 및 암세포에서의 유전자 발현의 검출 방법
US20070117123A1 (en) * 2005-09-14 2007-05-24 The Regents Of The University Of California Salivary protein and rna for breast cancer detection
KR100679173B1 (ko) * 2006-02-28 2007-02-06 주식회사 바이오인프라 위암 진단용 단백질 마커 및 이를 이용한 진단키트

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEELIMA DENDULURI ET AL.: "Circulating biomarkers of bevacizumab activity in patients with breast cancer.", CANCER BIOLOGY & THERAPY., vol. 7, no. 1, 1 January 2008 (2008-01-01), pages 15 - 20 *

Also Published As

Publication number Publication date
KR20090079845A (ko) 2009-07-22
WO2009091230A2 (ko) 2009-07-23
KR101122647B1 (ko) 2012-03-13

Similar Documents

Publication Publication Date Title
PH12014502507A1 (en) Anti-angiogenesis therapy for the treatment of breast cancer
WO2008104543A3 (en) Method for predicting the occurrence of metastasis in breast cancer patients
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
MX2011007578A (es) Metodos para diagnosticar y tratar la disfagia.
EA201791876A1 (ru) Моноклональные антитела к прогастрину и их применение
WO2007074193A3 (es) Método de análisis de expresión diferencial en cáncer colorectal
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
EP1937845A4 (en) MICRO-RNA-BASED METHOD AND COMPOSITIONS FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF BREAST CANCER
WO2009091230A3 (ko) 유방암 모니터링,진단 및 스크리닝용 단백질 마커 및 이를 이용한 유방암 모니터링,진단 및 스크리닝 방법
GB2467467A (en) Taz/wwtr1 for diagnosis and treatment of cancer
WO2011041336A3 (en) Treating notch1-antagonist-resistant cancer (s) using notch3 antagonists
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
WO2010101793A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
DK2041576T3 (da) Differentiel cytokinekspression i humane cancere
MX2013011431A (es) Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.
SG168430A1 (en) Molecular signature of human lung cancer initiating cells
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
MX2011008439A (es) Biomarcadores de proteina para el diagnostico de enfermedades de tejido blando y como objetivos terapeuticos para intervenciones de cuidado bucal.
EA201390530A1 (ru) Способ получения сополимера натрийкарбоксиметилцеллюлозы и госсипола и его применение в комплексной терапии пациентов с аутистическими расстройствами и когнитивными нарушениями
MX2014002762A (es) Uso de proteina c-met para predecir la eficacia de anticuerpos de factor de crecimiento de anti-hepatocitos (hgf) en pacientes con cancer esofagico y gastrico.
MX336476B (es) Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado.
EA201501095A1 (ru) Эффективное лечение нмрл и прогностический клинический маркер чувствительной к лечению опухоли
ATE530668T1 (de) Verfahren und kits zur brustkrebsprognose
WO2012078648A3 (en) Novel method of cancer diagnosis and prognosis and prediction of response to therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09703016

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09703016

Country of ref document: EP

Kind code of ref document: A2